1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study

LUIGI MENEGHINI; JASVINDER GILL; ARNAUD DAUCHY; ANDRIUS BACEVICIUS; JODI STRONG; TIMOTHY S. BAILEY

doi:10.2337/db19-1087-p

1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study

Diabetes ◽

10.2337/db19-1087-p ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 1087-P

Author(s):

LUIGI MENEGHINI ◽

JASVINDER GILL ◽

ARNAUD DAUCHY ◽

ANDRIUS BACEVICIUS ◽

JODI STRONG ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Insulin Glargine ◽

Real World ◽

First Generation ◽

Standard Of Care ◽

Control Study

Download Full-text

A pragmatic randomized clinical trial of insulin glargine 300 U/ mL vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the ACHIEVE Control study

Diabetes Obesity and Metabolism ◽

10.1111/dom.14152 ◽

2020 ◽

Vol 22 (11) ◽

pp. 2004-2012

Author(s):

Luigi F. Meneghini ◽

Sean D. Sullivan ◽

Gerry Oster ◽

Robert Busch ◽

Anna M. G. Cali ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Insulin Glargine ◽

Randomized Clinical Trial ◽

Basal Insulin ◽

First Generation ◽

Insulin Analogues ◽

Control Study

Download Full-text

Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study

Endocrinology Diabetes & Metabolism ◽

10.1002/edm2.306 ◽

2021 ◽

Author(s):

Sean D. Sullivan ◽

Nick Freemantle ◽

Rishab A. Gupta ◽

Jasmanda Wu ◽

Charlie J. Nicholls ◽

...

Keyword(s):

United States ◽

Type 2 Diabetes ◽

High Risk ◽

Insulin Glargine ◽

Real World ◽

First Generation ◽

Insulin Analogue ◽

The United States ◽

Risk Patients

Download Full-text

Insulin glargine 300 U/ mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14116 ◽

2020 ◽

Vol 22 (11) ◽

pp. 1995-2003

Author(s):

Luigi Meneghini ◽

Lawrence Blonde ◽

Jasvinder Gill ◽

Arnaud Dauchy ◽

Andrius Bacevicius ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Insulin Glargine ◽

Basal Insulin ◽

First Generation ◽

Real Life ◽

Insulin Analogues

Download Full-text

128-LB: Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation Basal Insulins (BI) in Insulin-Naïve Type 2 Diabetes (T2D) Patients (Pts) With and Without Cardiovascular Disease (CVD): Outcomes of the Randomized Pragmatic Real-Life Clinical Trial ACHIEVE Control

Diabetes ◽

10.2337/db19-128-lb ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 128-LB ◽

Cited By ~ 1

Author(s):

JUAN P. FRIAS ◽

PIERRE EVENOU ◽

DAVID DALTON ◽

KATHLEEN M. DUNGAN

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Clinical Trial ◽

Insulin Glargine ◽

First Generation ◽

Real Life

Download Full-text

1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S

Diabetes ◽

10.2337/db20-1038-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1038-P

Author(s):

LUIGI MENEGHINI ◽

ALICE CHENG ◽

PIERRE EVENOU ◽

JASVINDER GILL ◽

AYAD MOHAMED ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Function ◽

Insulin Glargine ◽

Basal Insulin ◽

First Generation ◽

Real Life ◽

Standard Of Care ◽

Insulin Analogs

Download Full-text

103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1

Diabetes ◽

10.2337/db21-103-lb ◽

2021 ◽

Vol 70 (Supplement 1) ◽

pp. 103-LB

Author(s):

EUGENE WRIGHT ◽

JASVINDER GILL ◽

SAMUEL HUSE ◽

XUAN LI ◽

TIMOTHY REID ◽

...

Keyword(s):

Type 2 Diabetes ◽

Health Care ◽

Insulin Glargine ◽

Resource Utilization ◽

Real World ◽

Basal Insulin ◽

First Generation ◽

Health Care Resource ◽

Health Care Resource Utilization

Download Full-text

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Current Medical Research and Opinion ◽

10.1080/03007995.2019.1708287 ◽

2020 ◽

Vol 36 (4) ◽

pp. 571-581 ◽

Cited By ~ 2

Author(s):

Nick Freemantle ◽

Didac Mauricio ◽

Andrea Giaccari ◽

Timothy Bailey ◽

Ronan Roussel ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Glargine ◽

Real World ◽

Standard Of Care

Download Full-text

Abstract #1151: Lower Risk of Hypoglycemia and Less Health Care Utilization in Basal Insulintreated Patients with Type 2 Diabetes (T2D) After Switching to Insulin Glargine 300 UNITS/ML (GLA-300) VS Other Basal Insulins in Real-World Clinical Settings

Endocrine Practice ◽

10.1016/s1530-891x(20)44281-8 ◽

2017 ◽

Vol 23 ◽

pp. 317-318

Author(s):

Fang Liz Zhou ◽

Fen Ye ◽

Vineet Gupta ◽

Rishab Gupta ◽

Jennifer Sung ◽

...

Keyword(s):

Type 2 Diabetes ◽

Health Care ◽

Health Care Utilization ◽

Insulin Glargine ◽

Real World ◽

Lower Risk ◽

Care Utilization ◽

Clinical Settings

Download Full-text

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

Diabetes ◽

10.2337/db18-1057-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 1057-P

Author(s):

SEAN D. SULLIVAN ◽

TIMOTHY S. BAILEY ◽

RONAN ROUSSEL ◽

FANG L. ZHOU ◽

ZSOLT BOSNYAK ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Clinical Outcomes ◽

Real World ◽

Insulin Detemir ◽

Insulin Degludec ◽

Subgroup Analyses

Download Full-text

2327-PUB: Real-World Patient-Reported Outcomes (PROs) with Insulin Glargine 300 U/ml (Gla-300) in Basal Bolus-Treated People with Type 2 Diabetes (T2DM): The MAGE Study

Diabetes ◽

10.2337/db19-2327-pub ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 2327-PUB ◽

Cited By ~ 1

Author(s):

ANN A. VERHAEGEN ◽

ANDRÉ SCHEEN ◽

KATHY C. ALEXANDRE ◽

JACQUES BRUHWYLER ◽

IDES M. COLIN

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Real World ◽

Patient Reported Outcomes ◽

Patient Reported ◽

Basal Bolus

Download Full-text